Organogenesis Holdings Inc
NASDAQ:ORGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Organogenesis Holdings Inc
Retained Earnings
Organogenesis Holdings Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Retained Earnings
-$3.1m
|
CAGR 3-Years
59%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Retained Earnings
-$15.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Retained Earnings
$13.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Retained Earnings
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Retained Earnings
$13.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Retained Earnings
$35.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
45%
|
|
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
See Also
What is Organogenesis Holdings Inc's Retained Earnings?
Retained Earnings
-3.1m
USD
Based on the financial report for Dec 31, 2025, Organogenesis Holdings Inc's Retained Earnings amounts to -3.1m USD.
What is Organogenesis Holdings Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
54%
Over the last year, the Retained Earnings growth was 92%. The average annual Retained Earnings growth rates for Organogenesis Holdings Inc have been 59% over the past three years , 54% over the past five years .
